

ASX Announcement
29 August 2012

Appendix 4E Preliminary Final Report

SIRTEX MEDICAL LIMITED ABN 35 078 166 122

Year Ended 30 June 2012

RESULTS FOR ANNOUNCEMENT TO MARKET

Results	30/06/12 \$'000	30/06/11 \$'000	% Movement	
Revenues from ordinary activities	86,575	72,954	up	18.7%
Profit after tax from ordinary activities	17,103	11,479	up	49.0%
Net profit for the period attributable to members	17,103	11,479	up	49.0%

Dividend Distribution	Cents per Share	Franked cents per share
Current Period		
Final dividend	tbd	tbd
Record date for determining entitlements to dividend	tbd	tbd
Payment date for dividend	tbd	tbd
Previous corresponding Period		
Final dividend - paid 21 October 2011	7.0	7.0

NTA Backing	30/06/12	30/06/11
Net Tangible asset backing per ordinary security	103.0 Cents	93.9 Cents

This report is based on the attached audited consolidated financial report.



ASX Announcement

29 August 2012

Sirtex Reports 2012 Full Year Financial Results

Dose sales	up	23 per cent
Revenue	up	18 per cent
Profit before tax	up	54 per cent
Net profit after tax	up	49 per cent
Cash Flow from Operations	up	31 per cent

Sirtex Medical Limited (ASX: SRX) today reported revenue growth of 18 per cent to \$83 million with record dose sales of 6,141 worldwide, up 23 per cent for the period ended 30 June 2012.

Profit before income tax was up 54 per cent to \$22 million. Net profit after tax was up 49 per cent to \$17 million. EPS is 30.7 cents and net tangible assets per share were 102.8 cents.

Sirtex Medical Limited Chief Executive Officer, Mr Gilman Wong said, "Our business has performed very well with dose sales improving in all regions. We continue to invest in and build our business with a focus on creating sustainable long-term growth through our ability to serve a growing global customer base providing clinically effective oncology solutions that help improve outcomes for patients with liver cancer.

"Guided by our **2020Vision** strategy, Sirtex is creating a scalable global infrastructure to meet significant future demand for our targeted radiation therapy in established and new markets worldwide". Mr Wong said.



Regional performance

In the US, the investment in sales and marketing support staff combined with a renewed focus to educate the referral and oncology communities delivered exceptional results. US dose sales grew 32 per cent to deliver \$57 million revenue. The business in Europe achieved dose sales growth of four per cent and \$22 million in revenue. We continued to invest in European support staff and prepare for growth ahead. The Asia Pacific region grew dose sales 37 per cent to reach \$4 million in revenue. Sirtex expects strong growth trends in all markets to continue in 2013.

Foundations for future growth

Sirtex continues to make the necessary investments in clinical studies, sales and marketing, manufacturing, and R&D to create the foundations for future expansion. During the year, the company invested \$8.5 million to support five major post-marketing clinical studies and we are expediting the development of new delivery technology for SIR-Spheres microspheres.

These programs aim to make the SIR-Spheres microspheres easier to administer and move it from a last line treatment to a preferred first line standard offered to a larger patient population. All clinical studies are recruiting well with the SIRFLOX clinical study due to complete recruitment within six months.

Higher manufacturing volumes reflected a minor increase in gross margin to 81 per cent compared to 80.8 per cent last year. As at 30 June 2012, Sirtex has no debt and a cash balance of \$49 million.

For further information please refer to the audited 2012 Annual Report attached, alternatively contact:

Gilman Wong
CEO Sirtex Medical Limited
(02) 9964 8400

Tim Allerton or Andrew Geddes
City PR
(02) 9267 4511

SIR-Spheres[®] is a registered trademark of Sirtex SIR-Spheres Pty Ltd.